Previous Close | 42.69 |
Open | 42.74 |
Bid | 42.72 x 800 |
Ask | 42.73 x 1000 |
Day's Range | 42.62 - 43.12 |
52 Week Range | 31.01 - 50.21 |
Volume | |
Avg. Volume | 3,814,360 |
Market Cap | 21.724B |
Beta (5Y Monthly) | 0.62 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.16 (2.72%) |
Ex-Dividend Date | Feb 29, 2024 |
1y Target Est | N/A |
DEERFIELD, Ill., March 27, 2024--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2024 Annual Meeting) in a virtual format on Tuesday, May 7, 2024 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the 2024 Annual Meeting. Online access to the 2024 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2024 Annual Meeting in person. The virtual format provides a convenien
DEERFIELD, Ill., February 29, 2024--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 4:00 p.m. Eastern Time.
Baxter to act as exclusive partner to Spectral for 10 years following PMX approval by U.S. FDATORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the “Amended Agreement”) with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (“Baxter”) (NYSE: BAX), or